In Brief: Estee Lauder
This article was originally published in The Rose Sheet
Estee Lauder: Acquiring worldwide retail distribution rights to one of Les Laboratoires AEterna's cosmetic ingredients under an agreement announced by AEterna May 29. Under the deal, Lauder will "collaborate in the development of therapeutic products with AEterna with the aim of creating strategic alliances with pharmaceutical companies," the Quebec-based biotechnology firm AEterna said. The two-year agreement allows Lauder to incorporate the undisclosed ingredient in the company's Estee Lauder, Clinique, Prescriptives, Origins and Aramis brands but leaves the rights for future pharmaceutical and aesthetical applications with AEterna. The biotech firm anticipates that the sale of the ingredient could "substantially" augment its cosmetic division's turnover, generating about $10 mil. in revenues over the next five years. AEterna noted that the partnership allows the firm to "accelerate the creation of strategic alliances with pharmaceutical companies for the development of therapeutic dermatology products"...
You may also be interested in...
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program
Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle
Weekly Trademark Review